Factory Price Ebselen CAS NO (60940-34-3) Available in Bulk Quantity

Ebselen (60940-34-3)

1. Chemical Identity: Ebselen is a synthetic organoselenium compound with the chemical formula C13H9NOSe and the CAS number 60940-34-3. It is characterized by its unique structure, containing a selenium atom within a selenazolidine ring fused to a benzene ring.

2. Discovery and Development: Ebselen was initially developed as a glutathione peroxidase mimic due to its ability to mimic the activity of the natural enzyme glutathione peroxidase. It was later found to possess a broad spectrum of pharmacological activities, including antioxidant, anti-inflammatory, and neuroprotective properties.

3. Mechanism of Action: Ebselen exerts its pharmacological effects primarily through its antioxidant and anti-inflammatory mechanisms. As a glutathione peroxidase mimic, it catalyzes the reduction of hydroperoxides, thereby preventing oxidative damage to biomolecules such as lipids, proteins, and DNA.

4. Antioxidant Activity: Ebselen's antioxidant activity stems from its ability to scavenge reactive oxygen species (ROS) and reactive nitrogen species (RNS), thereby reducing oxidative stress and protecting cells from oxidative damage. This property makes it a potential therapeutic agent for various oxidative stress-related diseases.

5. Anti-inflammatory Effects: In addition to its antioxidant activity, ebselen exhibits anti-inflammatory properties by modulating the activity of pro-inflammatory signaling pathways and cytokines. It inhibits the production of inflammatory mediators such as prostaglandins and leukotrienes, thereby attenuating inflammatory responses.

6. Neuroprotective Potential: Ebselen has garnered significant interest for its neuroprotective effects, particularly in the context of neurodegenerative diseases and neurological disorders. It demonstrates the ability to protect neurons from oxidative damage, reduce neuroinflammation, and promote neuronal survival and function.

7. Clinical Applications: Ebselen has been investigated for its therapeutic potential in various medical conditions, including stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, and psychiatric disorders. Clinical trials have explored its safety, efficacy, and tolerability in human subjects, with promising results in some cases.

8. Safety Profile: Ebselen exhibits a favorable safety profile in preclinical studies and early-phase clinical trials, with low toxicity and minimal adverse effects reported at therapeutic doses. However, further research is needed to fully assess its long-term safety and potential side effects in larger patient populations.

9. Drug Development Challenges: Despite its promising pharmacological properties, ebselen faces challenges in drug development and clinical translation, including formulation optimization, pharmacokinetic profiling, and regulatory approval processes. Addressing these challenges is essential for advancing ebselen-based therapeutics to market.

10. Future Perspectives: Continued research on ebselen and its derivatives holds promise for advancing our understanding of its pharmacological mechanisms and therapeutic potential. Further preclinical and clinical studies are needed to elucidate its efficacy in specific disease contexts and identify optimal therapeutic strategies for clinical use. Collaborative efforts between academia, industry, and regulatory agencies are essential for translating ebselen's therapeutic promise into clinical practice.